Acquisition Announced
Eli Lilly and Company acquisition of Merida Biosciences
US$2.9bn consideration
Announced 31 Aug 2026
Advisers
Merida Biosciences
Target
- Financial adviser
- Legal adviser
- Target
- Merida Biosciences
- Acquirer
- Eli Lilly and Company
- Target based in
- United States
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Drug Development
In the league tables
Similar deals
- Eli Lilly and Company acquisition of AtaiBeckley Jul 2026 · US$2.8bn · Biotech
- Gilead Sciences acquisition of Tubulis Apr 2026 · US$3.1bn · Biotech
- GSK acquisition of RAPT Therapeutics Jan 2026 · US$2.2bn · Biotech
- Eli Lilly and Company acquisition of Ajax Therapeutics Apr 2026 · US$2.3bn · Biotech
- argenx SE acquisition of Forte Biosciences Jul 2026 · US$2.2bn · Biotech
Sources
- 2026 Centerview Partners: Exclusive financial advisor to Merida on its sale to Eli Lilly centerviewpartners.com
- 31 Aug 2026 Goodwin Advises Merida Biosciences in up to $2.875 Billion Acquisition by Eli Lilly goodwinlaw.com
- 31 Aug 2026 Press release (PR Newswire), Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases prnewswire.com

